Ludwig Institute for Cancer Research Limited

Abbott Laboratories Corporation

Vegenics Limited

Christoph Renner

Antony Wilks Burgess

Andrew Ewart Scott

Gerd J Ritter

Lloyd J Old

Michael Pfreundschuh

Elisabeth Stockert

Marc Gregory Achen

Steven Alan Stacker

Con Panousis

Webster K Cavenee

Edouard Collins Nice

Achim Jungbluth

Terrance Grant Johns

George Mark

Anne Murray

Andrew Mark Scott

Stefan Bauer

Eliane Fischer

Peter Collins

Huei-Jen Su Huang

Thomas Wüest

Antony Ludwig Inst For Cancer Research Burgess

Andrew Ludwig Inst For Cancer Research Scott

Anthony Wilks Burgess

Terrance Grant Jonhs

Huei-Jen Huang

Elizabeth Stockert

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Specific binding proteins and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

Anti-fibroblast activation protein antibodies and methods and uses thereof

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Humanized GM-CSF antibodies

The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.

Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same

Fusion proteins of humanized g250 specific antibodies and uses thereof

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Chimerized GM-CSF antibodies

A group of proteins which are associated with T cell activation are disclosed, as are the nucleic acid molecules encoding them. Various uses of these materials are also discussed.

Isolated nucleic acids associated with T cell activation and uses thereof

Growing community of inventors

Homburg/Saar, Germany

Christoph Renner